MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

French biotech MaaT Phar­ma says its acute graft-ver­sus-host dis­ease treat­ment ex­ceed­ed ex­pec­ta­tions in a sin­gle-arm Phase 3 study in Eu­rope.

The com­pa­ny now in­tends to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.